Novel Methods to Reduce Children's Secondhand Smoke Exposure II (EZII)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01896518 |
Recruitment Status :
Completed
First Posted : July 11, 2013
Last Update Posted : March 15, 2018
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Secondhand Smoke | Drug: Nicotine polacrilex Drug: Tobacco lozenge | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 74 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Single (Investigator) |
Primary Purpose: | Prevention |
Official Title: | Novel Methods to Reduce Children's Secondhand Smoke Exposure II |
Actual Study Start Date : | November 2012 |
Actual Primary Completion Date : | December 2014 |
Actual Study Completion Date : | December 2014 |

Arm | Intervention/treatment |
---|---|
No Intervention: Counseling | |
Experimental: Nicotine lozenge
Participants will receive nicotine lozenge to use as needed for 12 weeks.
|
Drug: Nicotine polacrilex |
Experimental: Tobacco lozenge
Participants will receive tobacco lozenge to use as needed for 12 weeks.
|
Drug: Tobacco lozenge |
- Change in Child Salivary Cotinine [ Time Frame: 3, 6, and 12 weeks ]Child salivary cotinine will be measured to assess the level of secondhand smoke exposure. We will measure the change throughout the study.
- Change in Parent and Child Lung Function [ Time Frame: 3, 6, 12 weeks ]We will collect both parent and child spirometry data and compare changes.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 65 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
In order to be included in the study, participants must:
- be the primary caregiver(defined as a person who spends the most time with the child and spends a minimum of 4 hours per day in the presence of the child) of a child between the ages of 3-11 (if caregiver has more > 1 child between 3-11 years, we will include the youngest),
- smoke at least 10 cigarettes per day for the past year,
- indicate that they smoke around their child or in the car or home at least one time per week],
- have no intention of quitting smoking in the next 12-weeks,
- aged 18-65 years,
- be fluent in English,
- have no recent history of cardiovascular distress that may contraindicate medicinal nicotine lozenge use (heart attack in the past year, arrhythmia, uncontrolled hypertension),
- not currently pregnant, planning to become pregnant, or breastfeeding,
- do not use non-cigarette tobacco (cigars, chewing tobacco)
- have no prior use of any potential reduced exposure product,
- have no major psychiatric impairment, including psychosis, suicidality, and/or any current alcohol/drug abuse or dependence
Exclusion Criteria:
Does not meet all of the requirements of inclusion criteria

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01896518
United States, Oklahoma | |
The Children's Hospital at OU Medical Center | |
Oklahoma City, Oklahoma, United States, 73104 |
Principal Investigator: | Theodore Wagener, Ph.D. | OTRC, OU Children's Hospital Dept. of Pediatrics, OU Cancer Center |
Responsible Party: | University of Oklahoma |
ClinicalTrials.gov Identifier: | NCT01896518 |
Other Study ID Numbers: |
0642 1R21CA164521-01A1 ( U.S. NIH Grant/Contract ) |
First Posted: | July 11, 2013 Key Record Dates |
Last Update Posted: | March 15, 2018 |
Last Verified: | March 2018 |
Studies a U.S. FDA-regulated Device Product: | No |
second hand smoke exposure; children |
Nicotine Ganglionic Stimulants Autonomic Agents Peripheral Nervous System Agents Physiological Effects of Drugs |
Nicotinic Agonists Cholinergic Agonists Cholinergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action |